MedTrace Logo

V3: Vancouver-Victoria Valacyclovir Trial for Early Psychosis

NCT00175513 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2011-04-14

No results posted yet for this study

Summary

This is an 18 week (2 weeks run-in, 16 weeks double blind) trial, to determine if an antiviral drug, valacyclovir (Valtrex) is helpful in treating the symptoms of psychosis, a form of a mental disorder.

Conditions

Interventions

DRUG

Valacyclovir (Valtrex)

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • University of British Columbia

    lead OTHER

Principal Investigators

  • William Honer, MD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00175513 on ClinicalTrials.gov